[RFA-NS-27-007] HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)

Description

Titolo: HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) Numero dell'opportunità: RFA-NS-27-007 Stato: aperto (posted) Tipo di opportunità: Discretionary Ente: National Institutes of Health — Department of Health and Human Services Tipo di finanziamento: Cooperative Agreement Categoria: Health Programma (ALN): 93.213 Research and Training in Complementary and Integrative Health; 93.233 National Center on Sleep Disorders Research; 93.273 Alcohol Research Programs; 93.279 Drug Use and Addiction Research Programs; 93.395 Cancer Treatment Research; 93.837 Cardiovascular Diseases Research; 93.838 Lung Diseases Research; 93.839 Blood Diseases and Resources Research; 93.840 Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders; 93.846 Arthritis, Musculoskeletal and Skin Diseases Research; 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders; 93.865 Child Health and Human Development Extramural Research; 93.866 Aging Research; 93.867 Vision Research Pubblicato il: 2026-06-16 Scadenza per le domande: 2029-02-20 Finanziamento totale stimato: 11,000,000 USD Numero di finanziamenti attesi: 3 Cofinanziamento richiesto: no Chi può fare domanda: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Others (see text field entitled "Additional Information on Eligibility" for clarification); Native American tribal governments (Federally recognized); Small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; State governments; Public housing authorities/Indian housing authorities; City or township governments; County governments; Native American tribal organizations (other than Federally recognized tribal governments); Independent school districts; Private institutions of higher education; Public and State controlled institutions of higher education; Special district governments Altre condizioni di eleggibilità: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. Descrizione: The purpose of this Notice of Funding Opportunity (NOFO) is to support the preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics for the treatment of pain. The goal of the program is to accelerate the advancement of promising early-stage therapeutic candidates and facilitate their readiness for Phase II clinical trials. Applicants must have a promising small molecule or biologic lead candidate for optimization, a strong biological rationale for the proposed approach, and established assays to guide the optimization process. The scope of the program includes lead optimization, early-stage development activities, IND-enabling studies, development of pharmacodynamic and/or target engagement biomarkers, preparation and submission of an Investigational New Drug (IND) application, and Phase I clinical testing. This is a milestone-driven, phased cooperative agreement program that involves active participation by NIH program staff in project planning and ongoing monitoring of research progress. Contatto: [email protected]

Sectors

Source

Source: grants.gov